

An Efficient Approach to 3,4-Disubstituted Pyridin-2-ones. Formal Synthesis of Mappicine Ketone

Ching H. Lin, Min R. Tsai, Yung S. Wang, and Nein C. Chang*

Department of Chemistry, National Sun Yat-Sen University, Kaohsiung, Taiwan 804, Republic of China


ncchang@mail.nsysu.edu.tw

Received January 14, 2003

Treatment of 3,4-dihydro-3-tosylpyridin-2-one **5** with sodium hydride and then alkyl halides gave various 3,4-disubstituted pyridin-2-ones **6**. Formal synthesis of mappicine ketone (**1**) was also reported.

Six-membered nitrogen containing heterocycles has been intensively studied in the synthesis of alkaloids, and a great number of them have significant biological activities.^{1,2} It is well-known that the pyridin-2-one ring system is a valuable building block in natural product synthesis.³ Numerous methods for the preparation of substituted pyridin-2-one had been reported in the literature.⁴

In this paper, we described an efficient access to a variety of 3,4-disubstituted pyridin-2-ones **6**, which existed in many alkaloids such as mappicine ketone $\mathbf{1}^5$ and camptothecin $\mathbf{2}$.⁶ A formal synthesis of mappicine ketone **1** is also reported.




Previously, we reported an efficient route to the unsymmetrical glutarimides **3** with a sulfonyl group at the C-3 position.⁷ We further discovered that reaction of

(2) Strunz, G. M.; Findlay, J. A. *The Alkaloids*; Academic Press: New York, 1985; Vol. 26, p 89. Southon, I. W.; Buckingham, J. *Dictionary of Alkaloids*; Chapman and Hall: London, 1989. Daly, J. W. J. *Nat. Prod.* **1998**, *61*, 162.

(3) (a) Comins, D. L.; Hong, H.; Saha, J. K.; Jianhua, G. J. Org. Chem. 1994, 59, 5120.
(b) Comins, D. L.; Hong, H.; Jianhua, G. Tetrahedron Lett. 1994, 35, 5331.
(c) Bernstein, P. R.; Gomes, B. C.; Kosmider, B. J.; Vacek, E. P.; Williams, J. C. J. Med. Chem. 1995, 38, 212.
(d) Kozikowski, A. P.; Campiani, G.; Sun, L.-Q.; Wang, S.; Saxena, A.; Doctor, B. P. J. Am. Chem. Soc. 1996, 118, 11357.
(e) Williams, D. R.; Lowder, P. D.; Gu, Y.-G. Tetrahedron Lett. 1997, 38, 327.

(4) For recent examples of the synthesis of functionalized 2-pyridones, see: (a) Bondavalli, F.; Bruno, O.; Presti, E. L.; Menozzi, G.; Mosti, L. *Synthesis* **1999**, 1169. (b) Perrin, S.; Monnier, K.; Laude, B.; Kubicki, M.; Blacque, O. *Eur. J. Org. Chem.* **1999**, *297*, 7. (c) Furukawa, I.; Fujisawa, H.; Kawazome, M.; Nakai, Y.; Ohta, T. *Synthesis* **1998**, 1715. (d) Ciufolini, M. A.; Bouchu, D.; Rousset, L.; Penlou, S.; Narkunan, K.; Carles, L. *J. Org. Chem.* **2002**, *67*, 4304. (e) Shimizu, M.; Ogura, K.; Hachiya, I. *Org. Lett.* **2002**, *4* (16), 2755.

SCHEME 1



3 with sodium hydride and then with lithium aluminum hydride could regioselectively reduce various 3-sulfonyl glutarimides **3** to hydroxy piperidones **4**, which were further dehydrated to 3,4-dihydro-3-tosylpyridin-2-one **5** in the presence of boron trifluoride (Scheme 1).⁸

Herein, we further developed an efficient approach to 3,4-disubstituted pyridin-2-ones **6** starting from **5**. As shown in Scheme 2, reaction of 3,4-dihydro-3-tosylpyridin-2-one **5** with 2.2 equiv of sodium hydride at 25 °C in THF for 5 min, the resulting anion reacted with a variety of alkyl halides to afford the corresponding 3,4-disubstituted pyridin-2-ones **6** in good yield, presumably after alkylation, and dehydrosulfonation then followed (Scheme 2). Several examples were examined, and the results are listed in Table 1.

^{*} To whom correspondence should be addressed. Telephone: (+886)-75253913. Fax: (+886)-75253913.

Rubiralta, M.; Giralt, E.; Diez, A. Piperidine: Structure, Preparation, Reactivity, and Synthetic Applications of Piperidine and its Serivatives; Elsevier: Amsterdam, 1991.
 Strunz, G. M.; Findlay, J. A. The Alkaloids; Academic Press:

⁽⁵⁾ For recent examples of the synthesis of mappicine ketone, see: (a) Comins, D. L.; Saha, J. K. *J. Org. Chem.* **1996**, *61*, 9623. (b) Josien, H.; Curran, D. P. *Tetrahedron* **1997**, *53*, 8881. (c) Boger, D. L.; Hong, J. *J. Am. Chem. Soc.* **1998**, *120*, 1218. (d) Yadav, J. S.; Sarkar, S.; Chandrasekhar, S. *Tetrahedron* **1999**, *55*, 5449. (e) Greene, A. E.; Leue, S.; Genisson, Y.; Mekouar, K. J. Org. Chem. **2000**, *65*, 5212. (f) Ciufolini, M. A.; Bouchu, D.; Rousset, L.; Penlou, S.; Narkunan, K.; Carles, L. J. Org. Chem. **2002**, *67*, 4304.

⁽⁶⁾ The Camptothecins: Unfolding their Anticancer Potential; Liehr, J. G., Giovanella, B. C., Verschraegen, C. F., Eds. Ann. N. Y. Acad. Sci. **2000**, *922*, Du, W.; Curran, D. P. Org. Lett. **2002**, *4* (19), 3215.

⁽⁷⁾ Chang, M. Y.; Chang, B. R.; Tai, H. M.; Chang, N. C. *Tetrahedron Lett.* **2000**, *41*, 10273.

⁽⁸⁾ Chang, B. R.; Chen, C. Y.; Chang, N. C. Tetrahedron Lett. 2002, 43, 3233.


 TABLE 1. Reaction of 5 with Excess NaH and Various

 Alkyl Halide

compd	R ₁	R ₂	R ₃	product (yield %)
5a	_{جَ} جُ OBn	—СН3	Bn	6a (85) ^a
5b	ζζζς∽OBn	—СН3	PMB	6b (88) ^a
5c	ζζζζ∽OBn	in the second	Bn	6c (84) ^b
5d	ç. S. OBn	~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	Bn	6d (83) ^b
5e	ζζ ^ζ ∕OBn	o oEt	Bn	6e (82) ^b
5f	zz OBn	r ²	Bn	6f (81) ^b
5g	-C-OCH ₃	H ₃ —CH ₃	PMB	6g (86) ^a
5h	- С- ОСН3	H ₃ jo ^s	РМВ	6h (82) ^b
5i	\rightarrow	, r ^a t	Bn	6i (81) ^b
5j	\neg	—CH ₂ CH ₃	Bn	6j (82) ^b

 a Reaction at room temperature. b Reaction at reflux temperature.


SCHEME 2



The synthesis of mappicine ketone was carried out as depicted in Scheme 3. Debenzylation of **6a** with BCl₃ at -20 °C to 0 °C obtained alcohol **7a** in 85% yield, and treatment of **7a** with PCC furnished the corresponding aldehyde **8a** in 87% yield. Addition of ethylmagnesium bromide to **8a** in the presence of CeCl₃ gave alcohol **9a** in 71% yield,⁹ which was further oxidized with PCC to give ketone **10a** in 95% yield. Unfortunately, while we tried to debenzylate pyridinone **10a** with hydrogen gas at 1 atm in the presence of palladium hydroxide catalyst, the unexpected over reduced compound **11** (81%) was







mappicine ketone (1)

obtained as the major product accompanied with a small amount of **9a**.

12

To avoid this over reduction problem, we chose PMB as the N-protecting group. Following the same procedures as described above, pyridinone **10b** was prepared in 43% overall yield starting from **6b**. Finally, reaction of **10b** with TFA in a sealed tube at 100 °C provided the desired ketopyridinone **12** in 80% yield (Scheme 4).¹⁰

Since compound **12** had already been transformed into mappicine ketone (1),^{5a} a formal synthesis of **1** was accomplished.

In summary, we have successfully developed an efficient approach to 3,4-disubstituted pyridin-2-ones **6**. This methodology provides greater flexibility for incorporation of an alternative functionality at the 3- and 4-position and proved to be applicable for the synthesis of mappicine ketone (**1**). Further application of these results in the synthesis of analogues of the mappicine and camptothecin is currently underway in our laboratory.

Experimental Section

Before use, THF was distilled from a deep blue solution resulting from sodium and benzophenone under nitrogen. All reagents and solvents were obtained from commercial sources and used without further purification. Thin-layer chromatography (TLC) analysis was performed with precoated silica gel

⁽⁹⁾ Direct adding of ethylmagnesium bromide to ${\bf 8a}$ gave complex results.

⁽¹⁰⁾ Padwa, A.; Heidellbaugh, T. M.; Kuethe, J. T. *J. Org. Chem.* **2000**, *65*, 2368.

(60 f₂₅₄ plates), and column chromatography was carried out on silica (70–230 mesh). All reactions were performed under an atmosphere of nitrogen in dried (except those concerned with aqueous solutions) spherical flasks and stirred with magnetic bars.

General Procedure of Regioselective Reduction of Glutarimides 3 to 3,4-Dihydro-3-tosylpyridin-2-ones 5. To a suspension of sodium hydride (1.2 mmol, 60% dispersion in oil, was washed 3 times with dry hexane) in dry THF (10 mL) was added glutarimides 3 (1.0 mmol) at 25 °C for 5 min, and then 2.0 mmol equiv of LAH was added in one portion and further stirred for 0.5-1.0 h. The reaction was quenched with ammonium chloride solution (1 mL). The layers were separated, and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried, filtered, and concentrated. Without purification, crude 4 was treated with boron trifloride (catalyst) in 20 mL of CH₂- Cl_2 at 0 $^\circ\text{C}$ for 1 day and quenched with saturated aqueous sodium bicarbonate. The layer was separated, and aqueous layer was extracted with dichloromethane. The combined organic layers were washed with brine, dried, filtered, and concentrated. The crude product was purified by flash chromatography (hexane/AcOEt = 4:1) to afford dehydration product 5.

General Procedure to 3,4-Disubstituted Pyridin-2-one 6. A solution of **5** (1.0 mmol) in THF (20 mL) was added to a rapidly stirred suspension of sodium hydride (60% dispersion in mineral oil, 2.2 mmol). After the reaction mixture was stirred at room temperature for 10 min, 1.2 mmol of alkyl halide was then added to the suspension mixture. The mixture was stirred for 12 h, quenched with water (5 mL), and extracted with AcOEt (3 \times 20 mL). The organic layers were washed with brine, dried with anhydrous MgSO₄, filtered, and evaporated. The residue was purified by column chromatography on silica gel (elution with hexane/ethyl acetate = 2:1) to give pyridin-2-one **6**.

1-Benzyl-4-[(benzyloxy)methyl]-3-methyl-*1H***-pyridin-2-one (6a).** 85% yield; IR (CDCl₃, cm⁻¹) 1649; ¹H NMR (500 MHz, CDCl₃) δ 7.35–7.25 (m, 10 H), 7.15 (d, J = 7.0 Hz, 1 H), 6.37 (d, J = 7.0 Hz, 1 H), 5.11 (s, 2 H), 4.56 (s, 2 H), 4.40 (s, 2 H), 2.08 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 162.4, 145.7, 137.4, 136.4, 133.4, 128.5 (2C), 128.2 (2C), 127.9 (2C), 127.7, 127.6 (2C), 127.5, 125.6, 105.4, 72.6, 68.2, 52.2, 11.8; HRMS calcd for C₂₁H₂₁NO₂ (M⁺) 319.4024, found 319.4033.

4-[(Benzyloxy)methyl]-1-(4-methoxybenzyl)-3-methyl-*1H*-pyridin-2-one (6b). 88% yield; IR (CDCl₃, cm⁻¹) 1648; ¹H NMR (500 MHz, CDCl₃) δ 7.36–7.30 (m, 5 H), 7.26 (d, J = 8.5 Hz, 2 H), 7.16 (d, J = 7.5 Hz, 1 H), 6.85 (d, J = 8.5 Hz, 2 H), 6.37 (d, J = 7.5 Hz, 1 H), 5.07 (s, 2 H), 4.58 (s, 2 H), 4.41 (s, 2 H), 3.78 (s, 3 H), 2.08 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 162.6, 159.2, 145.8, 137.6, 133.4, 129.7 (2C), 128.6, 128.4 (2C), 127.8, 127.7 (2C), 125.8, 114.1 (2C), 105.5, 72.8, 68.4, 55.2, 51.9, 11.9; HRMS calcd for C₂₂H₂₃NO₃ (M⁺) 349.1678, found 349.1675.

3-Allyl-1-benzyl-4-[(benzyloxy)methyl]-*1H*-pyridin-2one (6c). 84% yield; IR (CDCl₃, cm⁻¹) 1647; ¹H NMR (500 MHz, CDCl₃) δ 7.36–7.26 (m, 10 H), 7.19 (d, J = 7.0 Hz, 1 H), 6.41 (d, J = 7.0 Hz, 1 H), 5.91–5.83 (m, 1 H), 5.14 (s, 2 H), 4.99–4.95 (m, 2 H), 4.56 (s, 2 H), 4.44 (s, 2 H), 3.35 (d, J = 6.0 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 162.1, 146.9, 137.6, 136.5, 134.8, 134.4, 128.8 (2C), 128.4 (2C), 128.1 (2C), 127.9, 127.8 (2C), 127.7, 127.3, 115.1, 105.5, 72.9, 67.8, 52.3, 30.5; HRMS calcd for C₂₃H₂₃NO₂ (M⁺) 345.1729, found 345.1731.

1,3-Dibenzyl-4-benzyloxymethyl-*1H***-pyridin-2-one (6d).** 83% yield; IR (CDCl₃, cm⁻¹); ¹H NMR (500 MHz, CDCl₃) δ 7.39–7.14 (m, 16 H), 6.42 (d, J = 7.0 Hz, 1 H), 5.17 (s, 2 H), 4.51 (s, 1 H), 4.43 (s, 2 H), 3.97 (s, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 162.6, 147.2, 139.7, 137.5, 136.5, 134.6, 128.8 (2C), 128.7, 128.6, 128.5 (2C), 128.4 (2C), 128.3 (2C), 128.1 (2C), 127.9, 127.8 (2C), 125.9, 105.6, 72.9, 68.2, 52.5, 31.8; MS (EI, 30 eV); 395 (M⁺, 6.4%), 91 (100%).

(1-Benzyl-4-benzyloxymethyl-2-oxo-1,2-dihydro-pyridin-3-yl)acetic Acid Ethyl Ester (6e). 82% yield; IR (CDCl₃, cm⁻¹) 1731, 1652; ¹H NMR (500 MHz, CDCl₃) δ 7.35–7.26 (m, 10 H), 7.22 (d, J= 7.5 Hz, 1 H), 6.37 (d, J= 7.5 Hz, 1 H), 5.14 (s, 2 H), 4.55 (s, 2 H), 4.42 (s, 2 H), 4.12 (q, J= 7.0 Hz, 2 H), 3.65 (s, 2 H), 1.22 (t, J= 7.0 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 170.8, 162.1, 147.9, 137.4, 136.2, 135.1, 128.8 (2C), 128.4 (2C), 128.1 (2C), 127.9 (2C), 127.8, 127.7, 123.3, 105.8, 72.8, 68.4, 60.8, 52.3, 32.0, 14.0; MS (EI, 30 eV); 391 (M⁺, 3.3%), 91 (100%).

1,3-Dibenzyl-4-(3-benzyloxy-propyl)-*1H*-pyridin-2one (6f). 81% yield; IR (CDCl₃, cm⁻¹) 1602; ¹H NMR (500 MHz, CDCl₃) δ 7.34–7.22 (m, 15 H), 7.11 (d, J = 7.0 Hz, 1 H), 6.02 (d, J = 7.0 Hz, 1 H), 5.14 (s, 2 H), 4.47 (s, 2 H), 4.04 (s, 2 H), 3.43 (t, J = 6.0 Hz, 2 H), 2.61 (t, J = 8.0 Hz, 2 H), 1.76 (m, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 162.8, 150.8, 140.6, 138.3, 136.7, 134.0, 129.2, 128.8 (2C), 128.4 (2C), 128.3 (2C), 128.2 (2C), 128.1 (2C), 127.9, 127.6 (2C), 127.6, 125.8, 108.1, 72.9, 69.2, 52.3, 32.1, 29.6, 29.4; HRMS calcd for C₂₉H₂₉NO₂ (M⁺) 423.2193, found 423.2197.

4-(3,4-Dimethoxtphenyl)-1-(4-methoxybenzyl)-3-methyl-1H-pyridin-2-one (6g). 86% yield; IR (CDCl₃, cm⁻¹) 1647, 1513; ¹H NMR (500 MHz, CDCl₃) δ 7.32 (d, J = 8.5 Hz, 2 H), 7.17 (d, J = 7.0 Hz, 1 H), 6.92–6.83 (m, 4 H), 6.79 (d, J = 2.0 Hz, 1 H), 6.10 (d, J = 7.0 Hz, 1 H), 5.10 (s, 2 H), 3.91 (s, 3 H), 3.87 (s, 3 H), 3.78 (s, 3 H), 2.13 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 163.0, 159.2, 148.8, 148.7, 148.5, 132.7, 132.0, 129.8 (2C), 128.6, 126.1, 120.8, 114.1 (2C), 111.5, 110.8, 108.5, 55.8, 55.8, 55.2, 51.8, 14.6; HRMS calcd for C₂₂H₂₃NO₄ (M⁺) 365.1623, found 365.1625.

3-Allyl-4-(3,4-dimethoxyphenyl)-1-(4-methoxybenzyl)-*1H*-pyridin-2-one (6h). 82% yield; IR (CDCl₃, cm⁻¹) 1644, 1614, 1513; ¹H NMR (500 MHz, CDCl₃) δ 7.32 (d, J = 8.5 Hz, 2 H), 7.20 (d, J = 6.5 Hz, 1 H), 6.90–6.86 (m, 5 H), 6.12–6.03 (m, 2 H), 5.12 (s, 2 H), 5.05–4.95 (m, 2 H), 3.92 (s, 3 H), 3.86 (s, 3 H), 3.80 (s, 3 H), 3.29 (d, J = 5.5 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 162.4, 159.3, 150.0, 148.8, 148.4, 136.7, 133.5, 131.7, 129.8 (2C), 128.6, 127.6, 120.4, 114.8, 114.1 (2C), 111.4, 110.8, 108.6, 55.8, 55.8, 55.2, 51.7, 32.7; HRMS calcd for C₂₄H₂₅-NO₄ (M⁺) 391.1784, found 391.1783.

3-Allyl-1-benzyl-4-phenyl-*1H***-pyridin-2-one (6i).** 81% yield; IR (CDCl₃, cm⁻¹) 1649; ¹H NMR (500 MHz, CDCl₃) δ 7.43–7.26 (m, 10 H), 7.21 (d, J=7.0 Hz, 1 H), 6.11 (d, J=7.0 Hz 1 H), 6.05–5.97 (m, 1 H), 5.20(s, 2 H), 4.96 (m, 2 H), 3.27 (d, J=6.0 Hz, 2 H); ¹³C NMR (125 MHz, CDCl₃) δ 162.5, 149.3, 139.6, 136.6, 133.1, 132.32, 128.8 (2C), 128.4 (2C), 128.3 (2C), 127.9 (2C), 127.8 (2C), 127.7, 108.7, 52.3, 21.6, 13.5; HRMS calcd for C₂₁H₁₉NO (M⁺) 301.1467, found 301.1470.

1-Benzyl-3-ethyl-4-phenyl-*1H***-pyridin-2-one (6j).** 82% yield; IR (CDCl₃, cm⁻¹) 1647; ¹H NMR (500 MHz, CDCl₃) δ 7.35–7.18 (m, 10 H), 7.08 (d, *J* = 7.0 Hz, 1 H), 5.98 (d, *J* = 7.0 Hz, 1 H), 5.10 (s, 2 H), 2.45 (q, *J* = 7.5 Hz, 2 H), 1.03 (t, *J* = 7.5 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 162.5, 149.2, 139.5, 136.6, 133.1, 132.2, 128.8 (2C), 128.4 (2C), 128.3, 127.9 (2C), 127.8, 127.7 (2C), 108.6, 52.2, 21.5, 13.4; HRMS calcd for C₂₀H₁₉NO (M⁺) 289.1448, found 289.1461.

1-Benzyl-4-(hydroxymethyl)-3-methyl-1H-pyridin-2one (7a). A solution (1.0 M) of BCl_3 in CH_2Cl_2 (0.95 mL) was added to a cooled solution (-20 °C) of 6a (200.0 mg, 0.63 mmol) in CH₂Cl₂ (20 mL). The reaction mixture was then warmed slowly to 0 °C (4 h) and quenched with saturated aqueous sodium bicarbonate. The layers were separated, and the aqueous layer was extracted with dichloromethane. The organic layers were washed with brine, dried, filtered, and concentrated. Flash chromatography (hexane/ethyl acetate = 1:1) of the residue followed by filtration through a silica gel column gave 122.8 mg of 7a (85%). IR (CDCl₃, cm⁻¹) 1721, 1643; ¹H NMR (500 MHz, CDCl₃) δ 7.34-7.26 (m, 5 H), 7.19 (d, J = 7.0 Hz, 1 H), 6.42 (d, J = 7.5 Hz, 1 H), 5.14 (s, 2 H), 4.58 (s, 2 H), 2.08 (s, 3 H); 13 C NMR (125 MHz, CDCl₃) δ 162.6, 148.2, 136.5, 133.8, 128.8 (2C), 128.0 (2C), 127.8, 124.9, 104.9, 61.4, 52.4, 11.7; HRMS calcd for C14H15NO2 (M⁺) 229.1096, found 229.1097.

4-(Hydroxymethyl)-1-(4-methoxybenzyl)-3-methyl-1H-

pyridin-2-one (**7b**). 86% yield; IR (CDCl₃, cm⁻¹) 1711, 1643; ¹H NMR (500 MHz, CDCl₃) δ 7.25 (d, J = 8.5 Hz, 2 H), 7.18 (d, J = 7.0 Hz, 1 H), 6.85 (d, J = 8.5 Hz, 2 H), 6.39 (d, J = 7.0Hz, 1 H), 5.06 (s, 2 H), 4.57 (s, 2 H), 3.78 (s, 3 H), 2.07 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 162.6, 159.3, 148.0, 133.6, 129.6 (2C), 128.6, 124.9, 114.1 (2C), 104.9, 61.5, 55.2, 52.0, 11.7; HRMS calcd for C₁₅H₁₇NO₃ (M⁺) 259.1208, found 259.1202.

1-Benzyl-3-methyl-2-oxo-1,2-dihydro-pyridine-4-carbaldehyde (8a). To a stirred solution of alcohol 7a (200.0 mg, 0.87 mmol) in 20 mL of dichloromethane at 25 °C under nitrogen was added Celite, pyridium chlorochromate (226.3 mg, 1.05 mmol). The reaction mixture was stirred for 1 day. The mixture was filtered through silica gel, and the solid was washed with hexane/ethyl acetate = 2:1. The filtrate was concentrated in vacuo, and the residue was purified by column chromatography on silica gel (elution hexane/ethyl acetate = 2:1) to give ketone 8a (172.0 mg, 87%). IR (CDCl₃, cm⁻¹) 1716, 1648; ¹H NMR (500 MHz, CDCl₃) δ 10.30 (s, 1 H), 7.26-7.19 (m, 5 H), 7.18 (d, J = 7.5 Hz, 1H), 6.45 (d, J = 7.0 Hz, 1 H), 5.07 (s, 2 H), 2.42 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 190.7, 163.4, 139.2, 135.7, 135.1, 134.3, 128.8 (2C), 128.1, 128.0 (2C), 101.7, 52.8, 11.02; HRMS calcd for C14H13NO2 (M⁺) 227.0946, found 227.0947.

1-(4-Methoxybenzyl)-3-methyl-2-oxo-1,2-dihydro-pyridine-4-carbaldehyde (8b). 87% yield; IR (CDCl₃, cm⁻¹) 1701, 1619; ¹H NMR (500 MHz, CDCl₃) δ 10.39 (s, 1 H), 7.28–7.24 (m, 3 H), 6.87 (d, J = 8.5 Hz, 2 H), 6.52 (d, J = 7.0 Hz, 1 H), 5.09 (s, 2 H), 3.79 (s, 3 H), 2.51 (s, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 190.8, 163.5, 159.5, 139.2, 135.2, 134.2, 129.8 (2C), 127.8, 114.3 (2C), 101.7, 55.2, 52.4, 11.0; HRMS calcd for C₁₅H₁₅NO₃ (M⁺) 257.1052, found 257.1052.

1-Benzyl-4-(1-hydroxypropyl)-3-methyl-1H-pyridin-2one (9a). A solution of 8a (150.1 mg, 0.66 mmol) in anhydrous THF (10 mL) under N₂ was added to anhydrous CeCl₃ (325.5 mg, 1.32 mmol). After 30 min, EtMgBr (3.0 M in THF, 0.33 mL) was added to the mixture and stirred at 25 °C for 1 h. The reaction mixture was quenched with the addition of saturated aqueous NH₄Cl (5 mL) and extracted with EtOAc $(3 \times 20 \text{ mL})$; the organic layer was dried MgSO₄ and concentrated under reduced pressure. Chromatography (SiO₂, hexane/ethyl acetate = $\hat{1:2}$) afforded **9a** (120.6 mg, 71%). IR (CDCl₃, cm⁻¹) 3021, 1617; ¹H NMR (500 MHz, CDCl₃) δ 7.34-7.27 (m, 5 H), 7.13 (d, J = 7.5 Hz, 1 H), 6.40 (d, J = 7.5 Hz, 1 H), 5.08 (dd, J = 15.3, 8.7 Hz, 2 H), 4.68 (dd, J = 7.5, 5.5 Hz, 1 H), 2.01 (s, 3 H), 1.67–1.60 (m, 2 H), 0.93 (t, J = 7.5 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 162.7, 152.1, 136.3, 133.5, 128.7 (2C), 128.2 (2C), 127.8, 124.7, 104.3, 70.8, 52.4, 29.9, 12.0, 9.9; HRMS calcd for $C_{16}H_{19}NO_2$ (M⁺) 257.1402, found 257.1410. Anal. Calcd for C₁₆H₁₉NO₂: C, 74.68; H, 7.44; N, 5.44. Found: C, 74.63; H, 7.19; N, 5.18.

4-(1-Hydroxypropyl)-1-(4-methoxybenzyl)-3-methyl-*IH*-**pyridin-2-one (9b).** 87% yield; IR (CDCl₃, cm⁻¹) 3020, 1613; ¹H NMR (500 MHz, CDCl₃) δ 7.26 (d, J = 8.5 Hz, 2 H), 7.16 (d, J = 7.0 Hz, 1 H), 6.86 (d, J = 8.5 Hz, 2 H), 6.37 (d, J = 7.0 Hz, 1 H), 5.08 (d, J = 14.0 Hz, 1 H), 5.01 (d, J = 14.0 Hz, 1 H), 4.74 (t, J = 7.0 Hz, 1 H), 3.79 (s, 3 H), 2.08 (s, 3 H), 1.68–1.63 (m, 2 H), 0.95 (t, J = 7.5 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 162.7, 159.3, 151.4, 133.5, 129.8 (2C), 128.5, 124.8, 114.1 (2C), 103.8, 71.1, 55.2, 51.9, 29.9, 12.0, 9.9; HRMS calcd for C₁₇H₂₁NO₃ (M⁺) 287.1512, found 287.1523. Anal. Calcd for C₁₇H₂₁NO₃: C, 71.06; H, 7.37; N, 4.87. Found: C, 71.33; H, 7.08; N, 4.74. **1-Benzyl-3-methyl-4-propionyl-***1H***-pyridin-2-one** (**10a**). A solution of **9a** (130.2 mg, 0.51 mmol) in CH₂Cl₂ (10 mL) was added to a mixture of PCC (131.4 mg, 0.61 mmol) and Celite in CH₂Cl₂ (10 mL). The reaction mixture was stirred overnight at room temperature and then filtered over a short pad of silica gel with hexane/ethyl acetate = 1:1 to provide 123.7 mg (95%) of pyridone **10a**. IR (CDCl₃, cm⁻¹) 1716, 1641; ¹H NMR (500 MHz, CDCl₃) δ 7.37–7.27 (m, 5 H), 7.22 (d, J = 7.5 Hz, 1 H), 6.06 (d, J = 7.5 Hz, 1 H), 5.14 (s, 2 H), 2.74 (q, J = 7.5 Hz, 2.0 H), 2.16 (s, 3 H), 1.17 (t, J = 7.5 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 205.5, 162.9, 147.1, 135.9, 134.4, 128.8 (2C), 128.2 (2C), 128.1, 126.6, 102.9, 52.6, 35.8, 13.9, 7.6; HRMS calcd for C₁₆H₁₇NO₂ (M⁺) 255.1252, found 255.1254.

1-(4-Methoxybenzyl)-3-methyl-4-propionyl-*1H***-pyridin-2-one (10b).** 91% yield; IR (CDCl₃, cm⁻¹) 1717, 1643; ¹H NMR (500 MHz, CDCl₃) δ 7.27 (d, J = 8.5 Hz, 2 H), 7.20 (d, J = 7.0 Hz, 1 H), 6.87 (d, J = 8.5 Hz, 2 H), 6.04 (d, J = 7.0 Hz, 1 H), 5.07 (s, 2 H), 3.74 (s, 3 H), 2.73 (q, J = 7.5 Hz, 2 H), 2.15 (s, 3 H), 1.17 (t, J = 7.5 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 205.6, 162.9, 159.4, 147.0, 134.2, 129.8 (2C), 128.0, 126.6, 114.2 (2C), 102.8, 55.2, 52.1, 35.8, 13.9, 7.6; HRMS calcd for C₁₇H₁₉-NO₃ (M⁺) 285.1357, found 285.1359.

3-Methyl-4-propyl-1H-pydidin-2-one 11. To a solution of 60.1 mg (0.23 mmol) of pyridinone **10a** in 7 mL of acetic acid was added a catalytic amount of Pd(OH)₂, and the reaction mixture was stirred under hydrogen overnight. After filtration of the catalyst, the solution was extracted with CH_2Cl_2 and washed with water. The organic layer was washed with brine, dried over MgSO₄, and concentrated under reduced pressure. The crude residue was subjected to flash silica gel chromatography to give 28.2 mg (81%) of **11** as a white solid: mp 108–109 °C. IR (CDCl₃, cm⁻¹) 3020, 1616; ¹H NMR (500 MHz, CDCl₃) δ 7.24 (d, J = 6.5 Hz, 1 H), 6.17 (d, J = 6.5 Hz, 1 H), 2.51 (t, J = 7.5 Hz, 2 H), 2.14 (s, 3 H), 1.59 (q, J = 7.5 Hz, 2 H), 0.98 (t, J = 7.5 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 164.6, 153.1, 130.1, 125.4, 109.7, 35.5, 22.4, 13.9, 11.7; HRMS calcd for C₉H₁₃NO (M⁺) 151.0997, found 151.0998.

3-Methyl-4-propionyl-1*H***-pyridin-2-one 12.** A solution of 50.3 mg (0.17 mmol) of **10b** in 12 mL of trifluoroacetic acid was heated in a sealed tube at 100 °C for 4 h. The mixture was cooled, the solvent was removed under reduced pressure, and the residue was chromatographed on silica gel to give 22.5 mg (80%) of pyridinone **12** as a white solid: mp 128–129 °C. IR (CDCl₃, cm⁻¹) 3690, 1706; ¹H NMR (500 MHz, CDCl₃) δ 7.34 (d, J = 6.5 Hz, 1 H), 6.19 (d, J = 6.5 Hz, 1 H), 2.77 (q, J = 7.0 Hz, 2 H), 2.14 (s, 3 H), 1.92 (t, J = 7.0 Hz, 3 H); ¹³C NMR (125 MHz, CDCl₃) δ 205.6, 165.4, 149.5, 131.8, 125.9, 103.9, 35.9, 13.1, 7.6; HRMS calcd for C₉H₁₁NO₂ (M⁺) 165.0790, found 165.0791.

Acknowledgment. The authors would like to thank the National Science Council of the Republic of China for financial support

Supporting Information Available: Additional spectroscopic data for compounds **12**, **10b**, **9b**, **8b**, **7b**, and **6b** (¹H NMR in CDCl₃). This material is available free of charge via the Internet at http://pubs.acs.org.

JO034042S